Gerresheimer AG
Thesis
Gerresheimer AG is positioned to benefit from the growing demand for biologics and GLP-1 drugs, which are expected to significantly increase their revenue and margins. The company has improved its financial metrics under new management, targeting a 15% blended pre-tax ROIC and a substantial increase in free cash flow as capex burdens ease. With a current trading multiple of 8-9 times EBITDA, there is potential for revaluation as they capture a larger share of the high-value solutions market.
Did it work?
No price performance or elapsed-time data is available, so the return leg of the thesis cannot be assessed. The thesis rests on several verifiable dynamics — GLP-1/biologics-driven revenue growth, progress toward a 15% blended pre-tax ROIC, rising free cash flow as capex eases, and a re-rating from 8-9x EBITDA — none of which can be confirmed or refuted with the information provided. Without evidence that these catalysts have played out or been invalidated, no verdict on success or failure is warranted.